Veritas In Silico Inc.
Research Veritas In Silico Inc. (130A.T) on Bullrun: market cap JPY 2.19B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker130A.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 2.19B
- Financial periodFY2025
- RevenueJPY 91.14M
- Revenue growth-53.2%
- Net income-JPY 425.67M
- Free cash flow-JPY 330.51M
Valuation Snapshot
latest market cap is JPY 2.19B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 91.14M | -JPY 425.67M | -JPY 330.51M | n/a | -65.62 | JPY 1.83B | n/a | JPY 1.78B |
| FY2024 | JPY 194.64M | -JPY 236.44M | -JPY 223.65M | n/a | -37.11 | JPY 2.17B | n/a | JPY 2.21B |
| FY2023 | JPY 360.36M | JPY 33.05M | JPY 66.68M | n/a | 6.01 | JPY 1.55B | n/a | JPY 1.58B |
| FY2022 | JPY 178.80M | -JPY 141.38M | -JPY 204.29M | n/a | -25.7 | JPY 1.48B | n/a | JPY 1.54B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 2.19B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Veritas In Silico Inc.
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has commercialization agreement with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Veritas In Silico Inc.'s market cap?
Veritas In Silico Inc.'s market capitalization is JPY 2.19B.
What does Veritas In Silico Inc. do?
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has commercialization agreement with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.